STAT+: Why one expert thinks Gilead can produce a $25 HIV prevention shot, help eradicate the disease in the U.S.

For the past few months, CVS Caremark has declined to add a groundbreaking HIV prevention drug from Gilead Sciences to its formularies.

Clinical trials showed the twice-a-year injectable, called Yeztugo, was highly effective in preventing the infectious disease, prompting enthusiasm about combating HIV globally. But the pharmacy benefits manager has argued that the $28,000 price tag — before any rebates or discounts — in the U.S. is too high.

Just the same, other large insurers have started to cover the drug, and Gilead has told Wall Street analysts that about 90% of the targeted patient population should have access by June 2026. However, some critics argue the price will make it difficult to contain the disease in the U.S.

Continue to STAT+ to read the full story…

​STAT Pharma: The science and business of new drug development